Form D · Biotechnology
Emergent BioSolutions Inc.
Gaithersburg, MD · CIK 0001367644
Offering snapshot reported Oct 30, 2018 · SEC filing
- Reported sold
- $47.9M Offering amount: $47.9M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 15, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 30, 2018 | Initial | $47,870,412 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-324664
Source: Form D, filed Oct 30, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel J Abdun Nabi | Director, Executive |
| Sue Bailey | Director |
| Fuad El Hibri | Director, Executive |
| Zsolt Harsanyi | Director |
| Jerome M Hauer | Director |
| Adam R Havey | Executive |
| George J. Joulwan | Director |
| Robert G Kramer | Executive |
| Richard S. Lindahl | Executive |
| Ronald B Richard | Director |
| Atul Saran | Executive |
| Katherine Strei | Executive |
| Louis W Sullivan | Director |
| Kathryn C Zoon | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
400 Professional Dr, Suite 400
Gaithersburg, MD, 20879
Gaithersburg, MD, 20879